+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2027

  • ID: 4760348
  • Report
  • Region: Global
  • 106 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie
  • Can-Fite Biopharma
  • Eli Lilly
  • Leo Pharma
  • Novartis
  • Sun Pharma
  • MORE
Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2027

Summary

There is a high level of unmet need that is beginning to be addressed by pharmaceutical companies and this in turn is driving the modest growth of the global Plaque psoriasis market. Global Plaque psoriasis market is expected to grow from $16.2bn in 2017 to $24.2bn in 2027 across the seven major markets (7MM - The US, France, Germany, Italy, Spain, the UK and Japan) at a compound annual growth rate of 4.1%.

Psoriasis is an incurable, chronic and systemic inflammatory skin disorder with a prevalence of 2-3% worldwide. The exact cause of psoriasis is unknown, although it is believed that environmental factors, skin barrier disruptions, and immune dysfunctions are key components that induce the development of psoriasis. The most common form of psoriasis is plaque psoriasis (psoriasis vulgaris), which is the focus of this report.

The Plaque psoriasis market is currently very dynamic, with novel pipeline therapies being developed. As well as the recent launch of UCB’s Cimzia and Sun Pharma’s Ilumya, will challenge the current tumor necrosis factor (TNF), IL-17 and IL-23 inhibitors, and small molecule compounds.

However, there are still a number of unmet clinical needs in the Plaque psoriasis market, especially relating to the lack of oral therapies and safe topical therapies. These needs have been emphasized by various key opinion leaders (KOLs) interviewed. Furthermore, KOLs have highlighted that there is a lack of safe and efficacious treatment alternatives for pregnant and breastfeeding women.

Blockbuster drugs such as Amgen’s Enbrel (etanercept), Janssen’s Remicade (infliximab) and AbbVie’s Humira (adalimumab) have dominated the Plaque psoriasis market for over 10 years. Nevertheless, this is set to change as there has been increasing development of new therapeutics, particularly within the IL-17 and IL-23 classes. Furthermore, companies are racing to bring their biosimilars to the market. As a result, it will be difficult for any one product to become and remain a market leader in a heavily competitive market.

There are many companies that are striving to enter the Plaque psoriasis market and many of the drugs target moderate and severe Plaque psoriasis patients. However, the most neglected segment is the mild severity. There are limited treatment options other than topical and small molecule therapeutics and this is a high unmet need.

The latest report "Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2027", provides key metrics for Plaque Psoriasis (Epidemiology, Market Size, Product Pipeline, Key Events, Competitive Analysis) in the seven major pharmaceutical markets (7MM) covered in this report-the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan-during the forecast period from 2017-2027.

Key Questions Answered
  • How will the Psoriasis market landscape in the 7MM (US, France, Germany, Italy, Spain, UK and Japan) change from 2017-2027?
  • What are the most promising late-stage pipeline drugs in Plaque Psoriasis?
  • How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another and against existing treatment options?
  • What are the greatest unmet needs in Plaque Psoriasis? Will the pipeline drugs fulfil these needs of the market?
  • What are the largest opportunities in the Plaque Psoriasis landscape?
Scope
  • Overview of Plaque psoriasis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline Plaque psoriasis market revenue from 2017-2027. ACOT and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting Plaque psoriasis therapeutics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global Plaque psoriasis therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Plaque psoriasis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Plaque psoriasis therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie
  • Can-Fite Biopharma
  • Eli Lilly
  • Leo Pharma
  • Novartis
  • Sun Pharma
  • MORE
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Plaque Psoriasis: Executive Summary
2.1 Moderate Growth Is Expected for the plaque psoriasis Market from 2017-2027
2.2 R&D Strategies Target Moderate to Severe Patients
2.3 Opportunities Remain for Novel Oral and Topical Therapies
2.4 Pipeline Agents Provide Improved Treatment Options in the Crowded Market
2.5 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for Plaque Psoriasis (20172027)
5.5.1 One-Year Diagnosed Prevalent Cases of Plaque Psoriasis
5.5.2 Age-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis
5.5.3 Sex-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis
5.5.4 One-Year Diagnosed Prevalent Cases of Plaque Psoriasis by Severity
5.5.5 One-Year Diagnosed Prevalent Cases of Plaque Psoriasis with PsA
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis

6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 Leading Prescribed Drugs and Treatment Guidelines
6.3 US
6.4 5EU
6.5 Japan

7 Competitive Assessment
7.1 Overview

8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Lack of Oral Therapies
8.3 Lack of New Topical Therapies
8.4 Safe and Efficacious Drugs for Pregnant Women
8.5 Treatment Options for Mild Plaque psoriasis Patients
8.6 Education and Treatment of Psychological Factors Accompanying Plaque psoriasis

9 Pipeline Assessment
9.1 Overview

10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Johnson & Johnson
10.3.2 AbbVie
10.3.3 Amgen
10.3.4 Novartis
10.3.5 Pfizer
10.3.6 Eli Lilly
10.3.7 Merck
10.3.8 Leo Pharma
10.3.9 Celgene
10.3.10 Can-Fite Biopharma
10.3.11 UCB
10.3.12 Sun Pharma

11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers

12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research - KOLs and Payers Interviewed for This Report
12.4.1 KOLs
12.4.2 Payers
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.6.1 Analyst
12.6.2 Therapy Area Director
12.6.3 Epidemiologist
12.6.4 Managing Epidemiologist
12.6.5 Global Director of Therapy Analysis and Epidemiology
12.6.6 Global Head and EVP of Healthcare Operations and Strategy
12.7 About the Publisher
12.8 Contact Us
12.9 Disclaimer

List of Tables
Table 1: Plaque Psoriasis: Key Metrics in the 7MM
Table 2: Classification of Plaque Psoriasis
Table 3: Risk Factors and Comorbidities for Plaque Psoriasis
Table 4: Treatment Guidelines for Psoriasis
Table 5: Country Profile - US
Table 6: Country Profile - 5EU
Table 7: Country Profile - Japan
Table 8: Leading Treatments for Plaque psoriasis, 2018
Table 9: Johnson & Johnson’s Plaque psoriasis Portfolio Assessment, 2018
Table 10: AbbVie’s Plaque psoriasis Portfolio Assessment, 2018
Table 11: Amgen’s Plaque psoriasis Portfolio Assessment, 2018
Table 12: Novartis’ Plaque psoriasis Portfolio Assessment, 2018
Table 13: Pfizer’s Plaque psoriasis Portfolio Assessment, 2018
Table 14: Eli Lilly’s Plaque psoriasis Portfolio Assessment, 2018
Table 15: Merck’s Plaque psoriasis Portfolio Assessment, 2018
Table 16: Leo Pharma’s Plaque psoriasis Portfolio Assessment, 2018
Table 17: Celgene’s Plaque psoriasis Portfolio Assessment, 2018
Table 18: Can-Fite Biopharma’s Plaque psoriasis Portfolio Assessment, 2018
Table 19: UCB’s Plaque psoriasis Portfolio Assessment, 2018
Table 20: Sun Pharma’s Plaque psoriasis Portfolio Assessment, 2018
Table 21: Plaque psoriasis Market - Global Drivers and Barriers, 2017-2027
Table 22: Key Events Impacting Sales for Plaque psoriasis in the US, 2017-2027
Table 23: Plaque psoriasis Market - Drivers and Barriers in the US, 2017-2027
Table 24: Key Events Impacting Sales for Plaque psoriasis in the 5EU, 2017-2027
Table 25: Plaque psoriasis Market - Drivers and Barriers in the 5EU, 2017-2027
Table 26: Key Events Impacting Sales for Plaque psoriasis in Japan, 2017-2027
Table 27: Plaque psoriasis Market - Global Drivers and Barriers in Japan, 2017-2027
Table 28: Key Historical and Projected Launch Dates for Plaque psoriasis
Table 29: Key Historical and Projected Patent Expiry Dates for Plaque psoriasis
Table 30: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales Forecast by Country for Plaque psoriasis in 2017 and 2027
Figure 2: Analysis of the Company Portfolio Gap in Plaque psoriasis During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents That the Author Expects to Be Launched for the Treatment of Plaque psoriasis During the Forecast Period
Figure 4: TNF Inhibitors and Interleukin Inhibitors in the Treatment of Plaque psoriasis
Figure 5: PDE4 Inhibitors in the Treatment of Plaque psoriasis
Figure 6: Age-Adjusted One-Year Diagnosed Prevalence of Plaque Psoriasis (%), Men and Women, Ages ≥18 Years, 2017
Figure 7: Sources Used and Not Used for One-Year Diagnosed Prevalent Cases of Plaque Psoriasis
Figure 8: Sources Used for One-Year Diagnosed Prevalent Cases of Plaque Psoriasis by Severity
Figure 9: Sources Used for One-Year Diagnosed Prevalent Cases of Plaque Psoriasis with PsA
Figure 10: One-Year Diagnosed Prevalent Cases of Plaque Psoriasis, 7MM, Men and Women, Ages ≥18 Years, 2017
Figure 11: Age-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis, 7MM, Men and Women, Ages ≥18 Years, 2017
Figure 12: Sex-Specific One-Year Diagnosed Prevalent Cases of Plaque Psoriasis, 7MM, Men and Women, Ages ≥18 Years, 2017
Figure 13: One-Year Diagnosed Prevalent Cases of Plaque Psoriasis by Severity, 7MM, Men and Women, Ages ≥18 Years, 2017
Figure 14: One-Year Diagnosed Prevalent Cases of Plaque Psoriasis with PsA, 7MM, Men and Women, Ages ≥18 Years, 2017
Figure 15: Diagnosis and Treatment of Plaque psoriasis
Figure 16: Unmet Needs and Opportunities in Plaque psoriasis
Figure 17: Overview of the Development Pipeline in Plaque psoriasis
Figure 18: Key Phase II/III Trials for the Promising Pipeline Agents that the Author Expects be Launched for Plaque psoriasis in the 7MM During the Forecast Period
Figure 19: Competitive Assessment of the Late-Stage Pipeline Agents that the Author Expects to be Launched for the Treatment of Plaque psoriasis During the Forecast Period
Figure 20: Analysis of the Company Portfolio Gap in Plaque psoriasis During the Forecast Period
Figure 21: Global (7MM) Sales Forecast by Country for Plaque psoriasis in 2017 and 2027
Figure 22: Sales Forecast by Class for Plaque psoriasis in the US in 2017 and 2027
Figure 23: Sales Forecast by Class for Plaque psoriasis in the 5EU in 2017 and 2027
Figure 24: Sales Forecast by Class for Plaque psoriasis in Japan in 2017 and 2027
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Johnson & Johnson
  • AbbVie
  • Amgen
  • Novartis
  • Pfizer
  • Eli Lilly
  • Merck
  • Leo Pharma
  • Celgene
  • Can-Fite Biopharma
  • UCB
  • Sun Pharma
Note: Product cover images may vary from those shown
Adroll
adroll